A new study is set to help people with Parkinson's disease regain their stride.

Researchers are conducting the first large-scale trial of a Functional Electrical Simulation (FES) device to help improve the walking ability of people with Parkinson’s disease.

The trial involves more than 200 people with Parkinson’s from eight sites around the UK.

The STEPS 2 trial is led by Professor Paul Taylor at Salisbury District Hospital, in partnership with the University of Southampton, University of Plymouth, and the University of Exeter.

Funding is provided by the National Institute for Health and Care Research (NIHR).

Professor Paul Taylor said: "Nearly four in ten people with Parkinson’s disease are recurrent fallers, experiencing an average of 21 falls a year.

"This can lead to a reduction in overall activity, fitness, health and social participation.

"Functional Electrical Stimulation is already recommended by NICE as an assistive device for people with dropped foot due to a stroke or MS, and we believe it could offer similar benefits to those with Parkinson’s disease."

The STEPS 2 trial follows a 2020 feasibility study (STEPS 1) where 64 people with Parkinson’s who had difficulty walking received FES in addition to standard care or standard care alone.

A significant number of those who received FES experienced increased walking speed and fewer falls.

Professor Maggie Donovan-Hall from the University of Southampton is a co-investigator on both trials.

She said: "Our feasibility study showed that people with Parkinson’s disease receiving FES walked faster, took larger strides, and had fewer falls.

"Interestingly, these benefits persisted even after some participants stopped using the device, indicating that it had a ‘training effect’."

David Muskett, 72, from Bournemouth, who was diagnosed with Parkinson’s disease 10 years ago, took part in the trial and has been using the FES device since June 2024.

He said: "The FES device has been an enormous help.

"It’s simple to set up, and I have been amazed at the difference it has made."

The trial is currently recruiting patients.

Details can be found on the University of Plymouth website.